By administering gefitinib together with hormone-depleted therapy for prostate cancer, it is expected that the switch to EGFR signaling via 3-O-sulfated HS will be suppressed and the development of CRPC will be prevented. This evidence concerns the gene EGFR and prostate carcinoma.